Posted by Michael Wonder on 15 Nov 2018
Merck begins rolling submission of licensure application for V920 (rVSV∆G-ZEBOV-GP) to U.S. FDA
13 November 2018 - V920 is the Company’s investigational vaccine for Ebola Zaire.
Merck today announced that it has started the submission of a rolling biologics license application to the U.S. FDA for V920 (rVSV∆G-ZEBOV-GP, live attenuated), the company’s investigational vaccine for Ebola Zaire disease. This rolling submission is made pursuant to the FDA’s breakthrough therapy designation for V920, which was announced by the company in July 2016.
Currently, Merck expects the rolling submission to be completed in 2019.
